APOC3 mRNA — Drug Target

All drugs that target APOC3 mRNA — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Antisense oligonucleotide

Phase 3 pipeline (3)

• Del-desiran (AOC 1001) · Avidity Biosciences, Inc. · Antisense oligonucleotide · Cardiovascular
  Del-desiran is an antisense oligonucleotide that reduces production of apolipoprotein C-III (apoC-III) to lower triglycerides and improve lipid metabolism.
• EZN-2279 · Leadiant Biosciences, Inc. · Antisense oligonucleotide · Cardiovascular
  EZN-2279 is an antisense oligonucleotide that inhibits apolipoprotein C-III (apoC-III) expression to reduce triglycerides and improve lipid metabolism.
• ION363 · Ionis Pharmaceuticals, Inc. · Antisense oligonucleotide · Cardiovascular
  ION363 is an antisense oligonucleotide that reduces production of apolipoprotein C-III (apoC-III), a protein that impairs triglyceride clearance and increases cardiovascular risk.